Ratings Novogene Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-04-29 EDT			5-day change	1st Jan Change
14.3 ^CNY	+1.20%		+5.38%	-38.73%

04-12	Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-27	Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

The firm trades with high earnings multiples: 28.04 times its 2024 earnings per share.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NOVOGENE CO., LTD.	-38.73%	816M		-
SONIC HEALTHCARE LIMITED	-18.36%	8.3B		B+
SYNLAB AG	-8.58%	2.47B		-
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B		B-
DR. LAL PATHLABS LIMITED	-10.06%	2.31B		B-
NEOGENOMICS, INC.	-5.44%	1.95B		C-
FLEURY S.A.	-17.79%	1.59B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B		C+
METROPOLIS HEALTHCARE LIMITED	+6.69%	1.1B		B+
ADICON HOLDINGS LIMITED	-23.31%	931M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality